Cyclacel Pharmaceuticals Announces Fourth Quarter Financial Results and Business Update
Berkeley Heights, N.J., April 02, 2025 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a pioneering biopharmaceutical company dedicated to the development of innovative medicines, recently disclosed its financial results for the fourth quarter ended December 31, 2024, and shared an update on its business progress.
Financial Highlights
For the fourth quarter, Cyclacel reported a net loss of $15.3 million, or $0.22 per share, compared to a net loss of $11.2 million, or $0.17 per share, in the same period a year ago. The increase in net loss was primarily due to higher research and development expenses, which totaled $11.5 million in the fourth quarter of 2024, compared to $8.5 million in the same quarter the previous year. Total revenue for the quarter was $0.1 million, down from $0.2 million in the fourth quarter of 2023.
Business Update
In the business update, Cyclacel shared that it has made significant strides in its clinical development programs. The Company’s lead product candidate, CYC065, is an oral selective CDK2/6 inhibitor currently in Phase 2 clinical trials for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Cyclacel also announced the initiation of a Phase 1b/2 clinical trial for CYC065 in combination with azacitidine for the treatment of older adults with MDS and AML.
Impact on Individuals
For individuals with MDS and AML, the progress of Cyclacel’s clinical trials for CYC065 holds potential implications. If successful, CYC065 could offer a new, effective treatment option for these diseases. As always, it is essential to consult with healthcare professionals for the most accurate and up-to-date information regarding treatments and potential implications.
- Individuals with MDS or AML may benefit from the development of a new treatment option.
- It is crucial to consult healthcare professionals for the most accurate and up-to-date information.
Impact on the World
The advancement of Cyclacel’s clinical trials for CYC065 could have significant implications for the global healthcare community. If successful, this new treatment option could help improve the lives of many individuals diagnosed with MDS and AML. Furthermore, the development of innovative medicines like CYC065 contributes to the overall progress of the biopharmaceutical industry.
- The development of new treatments for MDS and AML could improve the lives of countless individuals.
- Innovative medicines like CYC065 contribute to the overall progress of the biopharmaceutical industry.
Conclusion
Cyclacel Pharmaceuticals’ fourth quarter financial results and business update showcase the Company’s dedication to the development of innovative medicines, particularly its lead product candidate, CYC065. As this treatment moves through clinical trials for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), it holds the potential to significantly impact the lives of individuals diagnosed with these diseases. Furthermore, the progress of Cyclacel’s clinical trials contributes to the overall advancement of the biopharmaceutical industry.
Stay informed about the latest developments in the biopharmaceutical industry and the potential implications for individuals and the world by following trusted sources and consulting with healthcare professionals.
